Marker Therapeutics Inc (MRKR)

[Stockdoggy]

He has served on a lot of boards of companies that were bought out:

Mr. Elms currently serves as a director of ADMA Biologics, Ajax Health II and Zosano Pharma, and as a board observer of Marker Therapeutics and Verona Pharma. His prior board service includes Adams Respiratory Therapeutics, Advion BioSciences, Ambit Biosciences (acquired by Daiichi-Sankyo), Archimica Cooperatief (acquired by Euticals), Avera Pharmaceuticals, Bioenvision (acquired by Genzyme), CeNeRx BioPharma, Cidara Therapeutics, EarLens, LENSAR, Loxo Oncology (acquired by Eli Lilly), MAP Pharmaceuticals, NextWave Pharmaceuticals (acquired by Pfizer), Novazyme Pharmaceuticals (acquired by Genzyme), Oculex Pharmaceuticals (acquired by Allergan), Pernix Therapeutics, Scerene Healthcare and TRIA Beauty. He also serves on the INVO Board at Northwestern University.

Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.